查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1589264

囊腫纖維化市場：依藥物類別、給藥途徑- 2025-2030 年全球預測

Cystic Fibrosis Market by Drug Class (Bronchodilators, CFTR Modulators, Mucolytics), Route of Administration (Inhaled Drugs, Oral Drugs) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

囊腫纖維化市場2023年估值為58.8億美元，預計到2024年將達到64.4億美元，複合年成長率為9.53%，預計到2030年將達到111.3億美元。

囊腫纖維化(CF) 是一種影響呼吸和消化器官系統的遺傳性疾病，CFTR 基因突變會導致產生黏稠的黏液。解決 CF 的必要性在於它對患者的生活品質和預期壽命產生深遠影響，從而產生了對有效治療的巨大需求。該市場主要針對為管理和治療 CF 症狀而開發的藥品、診斷產品和醫療設備。最終使用者主要是需要對 CF 患者進行高級治療方法的醫院、診所和專科醫療機構。影響 CF 市場的關鍵成長要素包括由於診斷技術的改進而導致盛行率增加、製藥公司增加研發投資以及全球醫療基礎設施的加強。創新基因療法和個人化醫療方法的發展存在潛在的治療機會，CRISPR和mRNA技術的突破正在為CF的標靶治療鋪平道路。公司可以透過投資與研究機構的夥伴關係關係並優先考慮個人化醫療解決方案來抓住這些機會。然而，治療成本高、法律規範嚴格、新興市場認知度低等限制因素為市場擴張帶來了挑戰。此外，CF 的遺傳學很複雜，需要進行廣泛的研究才能充分了解突變特異性治療方法，這可能會減慢引入新治療方法的速度。創新的最佳領域包括基因編輯技術的進步、藥物傳遞系統的改進以及尋找罕見突變的新治療方法。詳細分析表明，在技術進步和對改進且易於使用的治療方法的持續需求的推動下，市場競爭激烈但充滿挑戰。策略聯盟、對前沿研究的持續投資以及提高全球知名度的努力對於利用市場機會和應對挑戰至關重要。

主要市場統計
基準年[2023] 58.8億美元
預測年份 [2024] 64.4億美元
預測年份 [2030] 111.3億美元
複合年成長率（%） 9.53%

市場動態：揭示快速發展的囊腫纖維化市場的關鍵市場洞察

供需的動態交互作用正在改變囊腫纖維化市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 囊腫纖維化盛行率增加和診斷技術的改進
    • 提高全球對囊腫纖維化的認知
    • 非政府組織、政府和私人公司的積極努力
  • 市場限制因素
    • 專利到期和學名藥
    • 基因突變率增加
  • 市場機會
    • 研發活動和強大的藥物開發平臺
    • 策略聯盟、併購的增加
  • 市場問題
    • 治療費用高、病理生理學複雜

波特的五力：駕馭囊腫纖維化市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解囊腫纖維化市場的外部影響

外部宏觀環境因素在塑造囊腫纖維化市場的表現動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析：了解囊腫纖維化市場的競爭格局

對囊腫纖維化市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣：囊腫纖維化市場供應商的績效評估

FPNV定位矩陣是評估囊腫纖維化市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：繪製囊腫纖維化市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對囊腫纖維化市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1.市場滲透率：對當前市場環境的詳細審查，主要企業的廣泛資料，評估他們在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 囊腫纖維化盛行率的增加和診斷技術的改進
      • 提高全球對囊腫纖維化的認知
      • 非政府組織、政府和私人公司的積極舉措
    • 抑制因素
      • 專利到期和學名藥
      • 基因突變率增加
    • 機會
      • 研發活動和強大的藥物開發平臺
      • 擴大策略合作、併購
    • 任務
      • 治療費用高且病理生理複雜
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章囊腫纖維化市場：依藥物類別

  • 介紹
  • 支氣管擴張劑
  • 囊腫纖維化治療劑
  • 黏液溶解藥物
  • 胰酵素補充品

第7章囊腫纖維化市場：依給藥途徑

  • 介紹
  • 吸入器
  • 口腔醫學

第8章美洲囊腫纖維化市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太囊腫纖維化市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章歐洲、中東和非洲囊腫纖維化市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • Alcresta Therapeutics, Inc.
  • AlgiPharma AS
  • AstraZeneca PLC
  • CHIESI Farmaceutici SpA
  • Elucigene Diagnostics by Delta Diagnostics (UK) Limited
  • F. Hoffmann-La Roche AG
  • Galapagos NV
  • Gilead Sciences, Inc.
  • Johnson & Johnson Services, Inc.
  • NovaBIoTics Ltd.
  • Novartis AG
  • Pharmaxis Ltd.
  • PTC Therapeutics, Inc.
  • Vertex Pharmaceuticals Incorporated
Product Code: MRR-4316E4E89581

The Cystic Fibrosis Market was valued at USD 5.88 billion in 2023, expected to reach USD 6.44 billion in 2024, and is projected to grow at a CAGR of 9.53%, to USD 11.13 billion by 2030.

Cystic Fibrosis (CF) is a genetic disorder that affects the respiratory and digestive systems, caused by mutations in the CFTR gene leading to the production of thick, sticky mucus. The necessity of addressing CF is underscored by its severe impact on patients' quality of life and life expectancy, creating a substantial demand for effective treatments. The market's application primarily lies within pharmaceuticals, diagnostics, and medical devices developed to manage and treat the symptoms of CF. End-use scopes are mainly hospitals, clinics, and specialty healthcare institutions that require advanced treatment options for CF patients. Key growth factors influencing the CF market include increasing prevalence due to improved diagnostic techniques, rising investments in research and development from pharmaceutical companies, and enhanced healthcare infrastructure globally. Potential opportunities lie in the development of innovative gene therapies and personalized medicine approaches, with breakthroughs in CRISPR and mRNA technology paving the way for targeted CF treatments. Companies can grab these opportunities by investing in partnerships with research institutions and prioritizing personalized healthcare solutions. However, limitations such as high treatment costs, stringent regulatory frameworks, and inadequate awareness in developing regions pose challenges to market expansion. The complexity of CF genetics also necessitates extensive research to fully comprehend mutation-specific therapies, potentially slowing the pace of new treatment introductions. Best areas for innovation include advancing gene editing technologies, improving drug delivery systems, and exploring novel therapeutics that address rare mutations. Detailed insights reveal a competitive yet rewarding market nature, driven by technological advances and a persistent demand for improved, accessible treatments. Strategic collaborations, continuous investment in cutting-edge research, and efforts to enhance global awareness are crucial for capitalizing on market opportunities and mitigating challenges.

KEY MARKET STATISTICS
Base Year [2023] USD 5.88 billion
Estimated Year [2024] USD 6.44 billion
Forecast Year [2030] USD 11.13 billion
CAGR (%) 9.53%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cystic Fibrosis Market

The Cystic Fibrosis Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of Cystic Fibrosis & improved diagnostic technologies
    • Increasing global awareness for Cystic Fibrosis
    • Favorable initiatives are taken by NGOs, government, and private companies
  • Market Restraints
    • Expiring patents and generic drugs
    • Increase in genetic mutation rate
  • Market Opportunities
    • Research & development activities and robust drug development pipeline
    • Growing strategic collaborations, merger, and acquisition
  • Market Challenges
    • High cost involved in treatment and complicated pathophysiology

Porter's Five Forces: A Strategic Tool for Navigating the Cystic Fibrosis Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cystic Fibrosis Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cystic Fibrosis Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cystic Fibrosis Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cystic Fibrosis Market

A detailed market share analysis in the Cystic Fibrosis Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cystic Fibrosis Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cystic Fibrosis Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cystic Fibrosis Market

A strategic analysis of the Cystic Fibrosis Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cystic Fibrosis Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alcresta Therapeutics, Inc., AlgiPharma AS, AstraZeneca PLC, CHIESI Farmaceutici S.p.A., Elucigene Diagnostics by Delta Diagnostics (UK) Limited, F. Hoffmann-La Roche AG, Galapagos NV, Gilead Sciences, Inc., Johnson & Johnson Services, Inc., NovaBiotics Ltd., Novartis AG, Pharmaxis Ltd., PTC Therapeutics, Inc., and Vertex Pharmaceuticals Incorporated.

Market Segmentation & Coverage

This research report categorizes the Cystic Fibrosis Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Bronchodilators, CFTR Modulators, Mucolytics, and Pancreatic Enzyme Supplements.
  • Based on Route of Administration, market is studied across Inhaled Drugs and Oral Drugs.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of Cystic Fibrosis & improved diagnostic technologies
      • 5.1.1.2. Increasing global awareness for Cystic Fibrosis
      • 5.1.1.3. Favorable initiatives are taken by NGOs, government, and private companies
    • 5.1.2. Restraints
      • 5.1.2.1. Expiring patents and generic drugs
      • 5.1.2.2. Increase in genetic mutation rate
    • 5.1.3. Opportunities
      • 5.1.3.1. Research & development activities and robust drug development pipeline
      • 5.1.3.2. Growing strategic collaborations, merger, and acquisition
    • 5.1.4. Challenges
      • 5.1.4.1. High cost involved in treatment and complicated pathophysiology
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cystic Fibrosis Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Bronchodilators
  • 6.3. CFTR Modulators
  • 6.4. Mucolytics
  • 6.5. Pancreatic Enzyme Supplements

7. Cystic Fibrosis Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Inhaled Drugs
  • 7.3. Oral Drugs

8. Americas Cystic Fibrosis Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Cystic Fibrosis Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Cystic Fibrosis Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Alcresta Therapeutics, Inc.
  • 3. AlgiPharma AS
  • 4. AstraZeneca PLC
  • 5. CHIESI Farmaceutici S.p.A.
  • 6. Elucigene Diagnostics by Delta Diagnostics (UK) Limited
  • 7. F. Hoffmann-La Roche AG
  • 8. Galapagos NV
  • 9. Gilead Sciences, Inc.
  • 10. Johnson & Johnson Services, Inc.
  • 11. NovaBiotics Ltd.
  • 12. Novartis AG
  • 13. Pharmaxis Ltd.
  • 14. PTC Therapeutics, Inc.
  • 15. Vertex Pharmaceuticals Incorporated

LIST OF FIGURES

  • FIGURE 1. CYSTIC FIBROSIS MARKET RESEARCH PROCESS
  • FIGURE 2. CYSTIC FIBROSIS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CYSTIC FIBROSIS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. CYSTIC FIBROSIS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. CYSTIC FIBROSIS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CYSTIC FIBROSIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CYSTIC FIBROSIS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CYSTIC FIBROSIS MARKET DYNAMICS
  • TABLE 7. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY BRONCHODILATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY MUCOLYTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY PANCREATIC ENZYME SUPPLEMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY INHALED DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ORAL DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 18. ARGENTINA CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 19. ARGENTINA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 20. BRAZIL CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 21. BRAZIL CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 22. CANADA CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 23. CANADA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 24. MEXICO CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 25. MEXICO CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. AUSTRALIA CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 33. AUSTRALIA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 34. CHINA CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 35. CHINA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. INDIA CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 37. INDIA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 38. INDONESIA CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 39. INDONESIA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 40. JAPAN CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 41. JAPAN CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 42. MALAYSIA CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 43. MALAYSIA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 44. PHILIPPINES CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 45. PHILIPPINES CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 46. SINGAPORE CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 47. SINGAPORE CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 48. SOUTH KOREA CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 49. SOUTH KOREA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. TAIWAN CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 51. TAIWAN CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 52. THAILAND CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 53. THAILAND CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 54. VIETNAM CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 55. VIETNAM CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. DENMARK CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 60. DENMARK CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 61. EGYPT CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 62. EGYPT CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 63. FINLAND CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 64. FINLAND CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. FRANCE CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 66. FRANCE CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. GERMANY CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 68. GERMANY CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 69. ISRAEL CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 70. ISRAEL CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. ITALY CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 72. ITALY CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. NETHERLANDS CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 74. NETHERLANDS CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 75. NIGERIA CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 76. NIGERIA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. NORWAY CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 78. NORWAY CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. POLAND CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 80. POLAND CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. QATAR CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 82. QATAR CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. RUSSIA CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 84. RUSSIA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. SAUDI ARABIA CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 86. SAUDI ARABIA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH AFRICA CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH AFRICA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. SPAIN CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 90. SPAIN CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. SWEDEN CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 92. SWEDEN CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. SWITZERLAND CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 94. SWITZERLAND CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. TURKEY CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 96. TURKEY CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED ARAB EMIRATES CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED ARAB EMIRATES CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED KINGDOM CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED KINGDOM CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 101. CYSTIC FIBROSIS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 102. CYSTIC FIBROSIS MARKET, FPNV POSITIONING MATRIX, 2023